Literature DB >> 19787776

Modeling G protein-coupled receptors for structure-based drug discovery using low-frequency normal modes for refinement of homology models: application to H3 antagonists.

Brajesh K Rai1, Gregory J Tawa, Alan H Katz, Christine Humblet.   

Abstract

G Protein-Coupled Receptors (GPCRs) are integral membrane proteins that play important role in regulating key physiological functions, and are targets of about 50% of all recently launched drugs. High-resolution experimental structures are available only for very few GPCRs. As a result, structure-based drug design efforts for GPCRs continue to rely on in silico modeling, which is considered to be an extremely difficult task especially for these receptors. Here, we describe Gmodel, a novel approach for building 3D atomic models of GPCRs using a normal mode-based refinement of homology models. Gmodel uses a small set of relevant low-frequency vibrational modes derived from Random Elastic Network model to efficiently sample the large-scale receptor conformation changes and generate an ensemble of alternative models. These are used to assemble receptor-ligand complexes by docking a known active into each of the alternative models. Each of these is next filtered using restraints derived from known mutation and binding affinity data and is refined in the presence of the active ligand. In this study, Gmodel was applied to generate models of the antagonist form of histamine 3 (H3) receptor. The validity of this novel modeling approach is demonstrated by performing virtual screening (using the refined models) that consistently produces highly enriched hit lists. The models are further validated by analyzing the available SAR related to classical H3 antagonists, and are found to be in good agreement with the available experimental data, thus providing novel insights into the receptor-ligand interactions. (c) 2009 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19787776     DOI: 10.1002/prot.22571

Source DB:  PubMed          Journal:  Proteins        ISSN: 0887-3585


  7 in total

1.  Computation of 3D queries for ROCS based virtual screens.

Authors:  Gregory J Tawa; J Christian Baber; Christine Humblet
Journal:  J Comput Aided Mol Des       Date:  2009-09-26       Impact factor: 3.686

Review 2.  Structure-Encoded Global Motions and Their Role in Mediating Protein-Substrate Interactions.

Authors:  Ivet Bahar; Mary Hongying Cheng; Ji Young Lee; Cihan Kaya; She Zhang
Journal:  Biophys J       Date:  2015-07-02       Impact factor: 4.033

3.  Ligand-based virtual screening approach using a new scoring function.

Authors:  Adel Hamza; Ning-Ning Wei; Chang-Guo Zhan
Journal:  J Chem Inf Model       Date:  2012-04-09       Impact factor: 4.956

4.  An NMR-based scoring function improves the accuracy of binding pose predictions by docking by two orders of magnitude.

Authors:  Julien Orts; Stefan Bartoschek; Christian Griesinger; Peter Monecke; Teresa Carlomagno
Journal:  J Biomol NMR       Date:  2011-12-14       Impact factor: 2.835

5.  Hybrid approach to structure modeling of the histamine H3 receptor: Multi-level assessment as a tool for model verification.

Authors:  Jakub Jończyk; Barbara Malawska; Marek Bajda
Journal:  PLoS One       Date:  2017-10-05       Impact factor: 3.240

6.  A unique ligand-steered strategy for CC chemokine receptor 2 homology modeling to facilitate structure-based virtual screening.

Authors:  Hongwei Jin; Jie Xia; Zhenming Liu; Xiang Simon Wang; Liangren Zhang
Journal:  Chem Biol Drug Des       Date:  2021-01-16       Impact factor: 2.817

7.  Synthesis and Characterization of a Bidirectional Photoswitchable Antagonist Toolbox for Real-Time GPCR Photopharmacology.

Authors:  Niels J Hauwert; Tamara A M Mocking; Daniel Da Costa Pereira; Albert J Kooistra; Lisa M Wijnen; Gerda C M Vreeker; Eléonore W E Verweij; Albertus H De Boer; Martine J Smit; Chris De Graaf; Henry F Vischer; Iwan J P de Esch; Maikel Wijtmans; Rob Leurs
Journal:  J Am Chem Soc       Date:  2018-03-14       Impact factor: 15.419

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.